Inhaled nitric oxide (NO) for vasoreactivity testing in pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 584s Year: 2003
Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013
Nitric oxide metabolite flux during exercise in pulmonary arterial hypertension Source: Annual Congress 2011 - Physiology of human pulmonary hypertension Year: 2011
Comparison of hemodynamic effects of inhaled nitric oxide (iNO) and inhaled epoprostenol (iEPO) in patients with pulmonary hypertension (PH) Source: Annual Congress 2011 - Treatment of pulmonary hypertension Year: 2011
The vasodilator response to inhaled nitric oxide (iNO) predicts the short term evolution with oral vasodilators in pulmonary arterial hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 3s Year: 2001
Exhaled nitric oxide levels in patients with pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016
Inhaled nitric oxide in patients with chronic thromboembolic pulmonary hypertension (CTEPH) Source: Eur Respir J 2006; 28: Suppl. 50, 399s Year: 2006
Feasibility of home treatment with inhaled nitric oxide for primary pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 598s Year: 2002
Fractional exhaled nitric oxide in chronic obstructive pulmonary disease Source: International Congress 2015 – Exhaled biomarkers in monitoring airways disease Year: 2015
Tolerance of long term nitric oxide treatment in severe arterial pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 370s Year: 2002
Infused nitric oxide in experimental pulmonary hypertension Source: Eur Respir J 2007; 30: Suppl. 51, 348s Year: 2007
Pathways in pulmonary arterial hypertension: the future is here Source: Eur Respir Rev 2012 21: 321-327 Year: 2012
Vasoreactivity to inhaled nitric oxide does not predict long term survival in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016
Nitric oxide vs prostacyclin in chronic high-flow pulmonary hypertension Source: Eur Respir J 2002; 20: Suppl. 38, 24s Year: 2002
Influence of inhaled nitric oxide on plasma endothelin-1 in pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 463s Year: 2003
The nitric oxide (NO) metabolites in monitoring and therapy of bronchial asthma Source: Annual Congress 2011 - Bronchial hyperresponsiveness and exhaled and sputum biomarkers Year: 2011
Measurement of gas transfer components using nitric oxide in post pulmonary endartectomy (PEA) chronic thromboembolic hypertension (CTEPH) patients Source: Annual Congress 2012 - Pulmonary circulation: clinical aspects of PAH, PTE and CTEPH Year: 2012
The effect of inhaled nitric oxide on the cardiac performance in patients with hypoxic pulmonary hypertension Source: Eur Respir J 2003; 22: Suppl. 45, 269s Year: 2003
Profiling nitric oxide metabolites in patients with idiopathic pulmonary arterial hypertension Source: Eur Respir J 2016; 48: 1386-1395 Year: 2016
Nitric oxide in acute testing in patients with pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 277s Year: 2004